What is GlycoMimetics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. GlycoMimetics's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. GlycoMimetics's Operating Income for the
three
months ended in Dec. 2023 was $ -9.59 Mil. GlycoMimetics's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate GlycoMimetics's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
GlycoMimetics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoMimetics (NAS:GLYC) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
GlycoMimetics's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-9.59 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $0.07 Mil.
GlycoMimetics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate GlycoMimetics's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. GlycoMimetics Inc has enough cash to cover all of its debt. Its financial situation is stable.
GlycoMimetics (GlycoMimetics) Business Description
Traded in Other Exchanges
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
Executives
| Edwin Rock |
officer: Chief Medical Officer |
9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
| Brian M. Hahn |
officer: CFO |
C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
| Daniel M Junius |
director |
C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
| Bruce S Johnson |
officer: SVP & Chief Commercial Officer |
9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850 |
| Chinmaya Rath |
officer: SVP and Chief Business Officer |
9708 MEDICAL CENTER DR., ROCKVILLE MD 20850 |
| Invus Public Equities, L.p. |
10 percent owner |
C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
| Invus Public Equities Advisors, Llc |
10 percent owner |
C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
| Artal Group S.a. |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| Artal International S.c.a. |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| S.a. Westend |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| Administratiekantoor Westend Stichting |
10 percent owner |
CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD |
| Artal International Management S.a. |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| Amaury Wittouck |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661 |
| Scott D Sandell |
10 percent owner |
|
| Harout Semerjian |
director, officer: Chief Executive Officer |
300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950 |
GlycoMimetics (GlycoMimetics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLYC has been successfully added to your 